Validation of AFP Model as a Predictor of Response, Recurrence and Survival in HCC Patients Underwent Locoregional Treatment

Background: incidence of hepatocellular carcinoma (HCC) has rapidly increased worldwide. HCC is the sixth most common malignancy and the third most common cause of cancer related death. Since HCC usually develops in a damaged liver, the prognosis of HCC depends not only on tumor progression but also on the degree of liver dysfunction. In Egypt, HCC constitutes 70.48% of all liver tumors among Egyptians. Aim of the Work: to validate the use of AFP model as a predictor of response, recurrence and survival in hepatocellular carcinoma patients after locoregional treatment. Patients and Methods: this study was conducted at Tropical Medicine department and HCC clinic, Ain Shams University Hospitals. The study was approved by the Research and Ethics Committee of Ain Shams University, Cairo, Egypt in accordance with local research governance requirements. Results: according to this classification 130 patients are for RFA and 70 patients are for TACE but actually 132 patients underwent TACE and 68 patients underwent RFA this could be explained by the facts that some lesions are large in size (>4cm) and others are located near main bile duct, intestinal loop or blood vessel so RFA couldn’t be done. Conclusion: AFP model may be a predictor of response, recurrence and survival in HCC patients undergoing locoregional treatment (TACE or RFA) but more studies with larger sample size are needed to validate its use.